Skip to main content

Table 2 Risk factor control and medication assessed at 3 and 12 months of follow-up

From: Long-term outcome of vertebral artery origin stenosis in patients with acute ischemic stroke

   Baseline 3-month follow-up 12-month follow-up
Asymptomatic VAO stenosis (n = 64) Systolic BP (mmHg) 151.0 ± 29.3 (n = 64) 124.5 ± 15.4 (n = 51)* 123.4 ± 13.8 (n = 42)*
Diastolic BP (mmHg) 84.6 ± 16.0 (n = 64) 71.0 ± 10.1 (n = 51)* 71.5 ± 8.8 (n = 42)*
Total cholesterol (mg/dl) 171.8 ± 36.7 (n = 63)   141.0 ± 34.7 (n = 49)*
LDL cholesterol (mg/dl) 107.9 ± 29.7 (n = 59)   80.7 ± 31.3 (n = 27)*
HDL cholesterol (mg/dl) 43.3 ± 10.5 (n = 63)   44.8 ± 11.7 (n = 48)
HbA1c (%)§ 8.0 ± 2.2 (n = 30)   7.0 ± 1.2 (n = 23)
Number of evaluated patients   55 45
 Antihypertensive drug (n,%)   42 (76.4) 37 (82.2)
 Antiplatelet agent or oral anticoagulant (n,%)   53 (96.4) 41 (91.1)
 Statin (n,%)   36 (65.5) 33 (73.3)
Symptomatic VAO stenosis (n = 73) Systolic BP (mmHg) 152.6 ± 22.6 (n = 73) 123.3 ± 16.0 (n = 57)* 125.6 ± 14.8 (n = 49)*
Diastolic BP (mmHg) 82.4 ± 15.3 (n = 73) 69.9 ± 9.7 (n = 57)* 72.8 ± 10.6 (n = 49)*
Total cholesterol (mg/dl) 185.8 ± 37.3 (n = 73)   148.0 ± 31.7 (n = 53)*
LDL cholesterol (mg/dl) 112.0 ± 31.2 (n = 70)   81.0 ± 27.5 (n = 30)*
HDL cholesterol (mg/dl) 44.9 ± 10.6 (n = 73)   47.1 ± 17.6 (n = 52)
HbA1c (%)§ 8.3 ± 1.7 (n = 35)   7.3 ± 0.9 (n = 22)
Number of evaluated patients   59 51
 Antihypertensive drug (n,%)   39 (66.1) 37 (72.5)
 Antiplatelet agent or oral anticoagulant (n,%)   58 (98.3) 49 (96.1)
 Statin (n,%)   45 (76.3) 39 (76.5)
  1. Values denote mean ± SD or numbers with percentages in parentheses. n number of evaluated patients.
  2. Significantly improved compared to profiles of the baseline: *p < 0.001, p < 0.01, p < 0.05.
  3. §HbA1c was measured in patients with diabetes mellitus.
  4. VAO vertebral artery origin.